Page 2 - Lora Grassilli News Today : Breaking News, Live Updates & Top Stories | Vimarsana

CAMBRIDGE, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Sath Shukla, President and Chief Executive Officer of Spero Therapeutics, will present and be available for one-on-one meetings at the H.C. Wainwright 25

SPA Agreement with FDA for Phase 3 PIVOT-PO Trial of Tebipenem HBr Phase 3 PIVOT-PO trial is expected to begin with First Patient, First Visit in 4Q 2023 Sath Shukla Became President and...

Phase3PIVOT-POtrialisexpectedtobeginwithFirstPatient,FirstVisitin4Q2023

Phase 2 trial of SPR720 in nontuberculous mycobacterial pulmonary disease on track for top line data readout in 1H 2024 Update on status of Special Protocol Assessment agreement for tebipenem HBr... | May 11, 2023

/PRNewswire/ -- Danone North America, today announced alongside its Specialized Nutrition business, Nutricia, the availability of Pepticate in the U.S. to help...